Nuwellis, Inc. (NASDAQ:NUWE) Stock Short Interest Climbs 118.9%

Nuwellis, Inc. (NASDAQ:NUWE – Get Free Report) saw a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 195,586 shares, a growth of 118.9% from the October 15th total of 89,357 shares. Based on an average trading volume of 3,723,204 shares, the days-to-cover ratio is currently 0.1 days. Approximately 36.8% of the company’s stock are sold short.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Nuwellis in a research report on Monday, September 21st. Wall Street Zen lowered shares of Nuwellis from a “hold” rating to a “sell” rating in a report on Saturday. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Get Our Latest Analysis on NUWE

Nuwellis Stock Performance

Shares of Nuwellis stock opened at $4.90 on Monday. The company has a fifty day simple moving average of $6.03 and a 200-day simple moving average of $206.53. Nuwellis has a 12-month low of $2.52 and a 12-month high of $1,556.07. The stock has a market cap of $2.65 million, a price-to-earnings ratio of -0.00 and a beta of 0.03.

Nuwellis (NASDAQ:NUWE – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($5.81) EPS for the quarter, topping the consensus estimate of ($122.85) by $117.04. Nuwellis had a negative net margin of 150.50% and a negative return on equity of 414.75%. The firm had revenue of $2.21 million for the quarter, compared to analyst estimates of $2.50 million.

Nuwellis Company Profile

(Get Free Report)

Nuwellis, Inc. is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated. Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs.

See Also

Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.